These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 30229512)

  • 21. Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors.
    Lee SJ; Lee SY; Lee WS; Yoo JS; Sun JM; Lee J; Park SH; Park JO; Ahn MJ; Lim HY; Kang WK; Park YS
    Invest New Drugs; 2017 Dec; 35(6):782-790. PubMed ID: 28391576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
    Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R
    Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas.
    Pishvaian M; Morse MA; McDevitt J; Norton JD; Ren S; Robbie GJ; Ryan PC; Soukharev S; Bao H; Denlinger CS
    Clin Colorectal Cancer; 2016 Dec; 15(4):345-351. PubMed ID: 27591895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
    Weiner LM; Clark JI; Davey M; Li WS; Garcia de Palazzo I; Ring DB; Alpaugh RK
    Cancer Res; 1995 Oct; 55(20):4586-93. PubMed ID: 7553634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors.
    Strickler JH; LoRusso P; Salgia R; Kang YK; Yen CJ; Lin CC; Ansell P; Motwani M; Wong S; Yue H; Wang L; Reilly E; Afar D; Naumovski L; Ramanathan RK
    Mol Cancer Ther; 2020 May; 19(5):1210-1217. PubMed ID: 32127466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies.
    Jayson GC; Zweit J; Jackson A; Mulatero C; Julyan P; Ranson M; Broughton L; Wagstaff J; Hakannson L; Groenewegen G; Bailey J; Smith N; Hastings D; Lawrance J; Haroon H; Ward T; McGown AT; Tang M; Levitt D; Marreaud S; Lehmann FF; Herold M; Zwierzina H;
    J Natl Cancer Inst; 2002 Oct; 94(19):1484-93. PubMed ID: 12359857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
    Moore KN; Borghaei H; O'Malley DM; Jeong W; Seward SM; Bauer TM; Perez RP; Matulonis UA; Running KL; Zhang X; Ponte JF; Ruiz-Soto R; Birrer MJ
    Cancer; 2017 Aug; 123(16):3080-3087. PubMed ID: 28440955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors.
    Moore KN; Bendell JC; LoRusso PM; Olszanski AJ; Zwick-Wallasch E; Jansen M; Vandell AG; Senaldi G
    Invest New Drugs; 2019 Feb; 37(1):147-158. PubMed ID: 30056611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
    Strickler JH; Weekes CD; Nemunaitis J; Ramanathan RK; Heist RS; Morgensztern D; Angevin E; Bauer TM; Yue H; Motwani M; Parikh A; Reilly EB; Afar D; Naumovski L; Kelly K
    J Clin Oncol; 2018 Nov; 36(33):3298-3306. PubMed ID: 30285518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors.
    Denlinger CS; Keedy VL; Moyo V; MacBeath G; Shapiro GI
    Invest New Drugs; 2021 Dec; 39(6):1604-1612. PubMed ID: 34250553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors.
    Smith DC; Eisenberg PD; Manikhas G; Chugh R; Gubens MA; Stagg RJ; Kapoun AM; Xu L; Dupont J; Sikic B
    Clin Cancer Res; 2014 Dec; 20(24):6295-303. PubMed ID: 25324140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors.
    Diaz LA; Coughlin CM; Weil SC; Fishel J; Gounder MM; Lawrence S; Azad N; O'Shannessy DJ; Grasso L; Wustner J; Ebel W; Carvajal RD
    Clin Cancer Res; 2015 Mar; 21(6):1281-8. PubMed ID: 25398449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer.
    McHugh D; Eisenberger M; Heath EI; Bruce J; Danila DC; Rathkopf DE; Feldman J; Slovin SF; Anand B; Chu R; Lackey J; Reyno L; Antonarakis ES; Morris MJ
    Invest New Drugs; 2019 Oct; 37(5):1052-1060. PubMed ID: 30725389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.
    Dowlati A; Harvey RD; Carvajal RD; Hamid O; Klempner SJ; Kauh JSW; Peterson DA; Yu D; Chapman SC; Szpurka AM; Carlsen M; Quinlan T; Wesolowski R
    Invest New Drugs; 2021 Aug; 39(4):1057-1071. PubMed ID: 33624233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.
    Baird RD; Linossi C; Middleton M; Lord S; Harris A; Rodón J; Zitt C; Fiedler U; Dawson KM; Leupin N; Stumpp MT; Harstrick A; Azaro A; Fischer S; Omlin A
    J Clin Oncol; 2021 Jan; 39(2):145-154. PubMed ID: 33301375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies.
    Weiner LM; Belldegrun AS; Crawford J; Tolcher AW; Lockbaum P; Arends RH; Navale L; Amado RG; Schwab G; Figlin RA
    Clin Cancer Res; 2008 Jan; 14(2):502-8. PubMed ID: 18223225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.
    Drevs J; Siegert P; Medinger M; Mross K; Strecker R; Zirrgiebel U; Harder J; Blum H; Robertson J; Jürgensmeier JM; Puchalski TA; Young H; Saunders O; Unger C
    J Clin Oncol; 2007 Jul; 25(21):3045-54. PubMed ID: 17634482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study.
    LoRusso PM; Krishnamurthi S; Youssoufian H; Hall N; Fox F; Dontabhaktuni A; Grebennik D; Remick S
    Invest New Drugs; 2014 Apr; 32(2):303-11. PubMed ID: 23903897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.
    Doi T; Iwasa S; Muro K; Satoh T; Hironaka S; Esaki T; Nishina T; Hara H; Machida N; Komatsu Y; Shimada Y; Otsu S; Shimizu S; Watanabe M
    Gastric Cancer; 2019 Jul; 22(4):817-827. PubMed ID: 30515672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.
    Strauss J; Heery CR; Schlom J; Madan RA; Cao L; Kang Z; Lamping E; Marté JL; Donahue RN; Grenga I; Cordes L; Christensen O; Mahnke L; Helwig C; Gulley JL
    Clin Cancer Res; 2018 Mar; 24(6):1287-1295. PubMed ID: 29298798
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.